Fibronectin-Enriched Interface Using a Spheroid-Converged Cell Sheet for Effective Wound Healing.

Area of Science:

• Regenerative Medicine
• Biomaterials Science
• Stem Cell Therapy

Background:

• Cell sheets and spheroids show promise for tissue healing but suffer from low cell loading and extracellular matrix (ECM) production.
• Light preconditioning enhances cell-based therapies via reactive oxygen species (ROS) but lacks precise control.
• Current methods face challenges in optimizing ROS levels for therapeutic cell signaling.

Purpose of the Study:

• To develop a novel microstructure (MS) patch for culturing spheroid-attached cell sheets, termed human mesenchymal stem cell complex (hMSCcx).
• To investigate the ROS tolerance and therapeutic efficacy of hMSCcx, particularly after light illumination.
• To enhance wound healing outcomes using the developed hMSCcx and MS patch system.

Main Methods:

• Development of a microstructure (MS) patch for culturing spheroid-attached cell sheets (hMSCcx).
• Assessment of ROS tolerance and antioxidant capacity of hMSCcx compared to standard cell sheets.
• Light (610 nm) illumination of hMSCcx to modulate ROS levels and evaluate angiogenic efficacy.
• Analysis of fibronectin expression and gap junctional communication.
• In vivo testing of hMSCcx engraftment and wound healing in a mouse model.

Main Results:

• The spheroid-converged structure of hMSCcx demonstrated superior ROS tolerance due to high antioxidant capacity.
• Light illumination of hMSCcx enhanced therapeutic angiogenic efficacy by regulating ROS without cytotoxicity.
• Illuminated hMSCcx showed increased fibronectin and enhanced gap junctional interaction, contributing to improved therapeutic effects.
• The novel MS patch facilitated improved hMSCcx engraftment, leading to robust wound healing in a mouse model.

Conclusions:

• The developed hMSCcx cultured on an MS patch offers a promising strategy to overcome limitations of conventional cell sheet and spheroid therapies.
• Light-mediated ROS regulation in hMSCcx enhances angiogenic potential and wound healing capabilities.
• This approach provides a new method for improving cell-based therapeutic outcomes in regenerative medicine.